Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

2. Constipation

Constipation Constipation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Constipation Last reviewed: September 2018 Last updated: October 2018 Summary A detailed history and physical examination, including a digital rectal examination, is the first step in the evaluation of constipation. Diagnostic evaluation may include a colonoscopy if indicated, colonic transit study, anorectal manometry, and a balloon expulsion (...) study. Initial treatment consists of lifestyle modification and laxatives. Medical treatment should be tailored to the underlying aetiology. Patients who do not respond to medical treatment may need specialised evaluation for pelvic floor dysfunction and biofeedback therapy. Surgery is only rarely indicated. Definition Chronic constipation is a polysymptomatic heterogeneous disorder. Patients define constipation on the basis of excessive straining, a sense of incomplete evacuation, failed or lengthy

BMJ Best Practice2018

3. Constipation

Constipation Top results for constipation - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for constipation The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

4. Constipation

Constipation Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

Trip Evidence Maps2018

5. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis

Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis 29730600 2018 06 06 1468-3288 2018 May 05 Gut Gut Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. gutjnl-2018-316001 10.1136/gutjnl-2018-316001 Opioids are increasingly prescribed in the West and have deleterious GI consequences. Pharmacological therapies to treat opioid-induced (...) constipation (OIC) are available, but their relative efficacy is unclear. We performed a systematic review and network meta-analysis to address this deficit in current knowledge. We searched MEDLINE, EMBASE, EMBASE Classic and the Cochrane central register of controlled trials through to December 2017 to identify randomised controlled trials (RCTs) of pharmacological therapies in the treatment of adults with OIC. Trials had to report a dichotomous assessment of overall response to therapy, and data were

EvidenceUpdates2018

6. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials 29545635 2018 03 16 1572-0241 2018 Mar 15 The American journal of gastroenterology Am. J. Gastroenterol. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. 10.1038/s41395-018-0026-7 Two identical, phase 3, randomized, double (...) -blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end point was the percentage of overall responders (patients reporting ≥30% reduction from baseline in worst abdominal pain plus an increase of ≥1 complete spontaneous bowel movement (CSBM)/week from baseline

EvidenceUpdates2018

7. Management of constipation in patients with Parkinson’s disease

Management of constipation in patients with Parkinson’s disease Management of constipation in patients with Parkinson’s disease | npj Parkinson's Disease Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. A Nature (...) Research Journal Management of constipation in patients with Parkinson’s disease , , , & , npj Parkinson's Disease volume 4 , Article number: 6 ( 2018 ) | Subjects Abstract A considerable body of research has recently emerged around nonmotor symptoms in Parkinson’s disease (PD) and their substantial impact on patients’ well-being. A prominent example is constipation which occurs in up to two thirds of all PD-patients thereby effecting psychological and social distress and consequently reducing quality

NPJ Parkinson's disease2018 Full Text: Link to full Text with Trip Pro

8. Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects

Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects application/xhtml+xml; charset=utf-8

International journal of chronic diseases2018 Full Text: Link to full Text with Trip Pro

9. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis

Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis 29380823 2018 03 16 1572-0241 113 3 2018 Mar The American journal of gastroenterology Am. J. Gastroenterol. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. 329-338 10.1038/ajg.2017.495 (...) Linaclotide and plecanatide are guanylate cyclase-C (GCC) agonists for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Our objective is to evaluate the efficacy and tolerability of GCC agonists based on data from multiple randomized controlled trials (RCTs). We searched PubMED, EMBASE, Cochrane databases, clinicaltrials.gov, major conference abstracts, Food and Drug Administration (FDA) websites, and United States Securities and Exchange

EvidenceUpdates2018

10. The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation

The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation ORIGINAL RESEARCH ARTICLE The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation Becky Pennington 1 • Emily-Ruth Marriott 1 • Peter Lichtlen 2 • Ayesha Akbar 3,4 • Anthony J. Hatswell 1,5 Published online: 4 January 2018 The Author(s) 2018. This article is an open access publication Abstract Objective The objective of this study was to evaluate the cost effectiveness of lubiprostone, prucalopride (...) , placebo and immediate referral to secondary care in chronic idio- pathic constipation (CIC) in an economic model that was used by the UK National Institute for Health and Care Excellence (NICE) in developing guidance. Methods We developed a cohort state-transition model to re?ect thetreatment pathway inCICfrom theUKNHS and personal social services perspective. Time on treatment was determined by a treatment continuation rule using data from an indirect comparison and survival curves ?tted to long-term

PharmacoEconomics open2018 Full Text: Link to full Text with Trip Pro

11. Constipation

Constipation Constipation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Constipation Last reviewed: August 2018 Last updated: March 2018 Summary Chronic constipation is a heterogeneous disorder, and patients commonly report one or more of the following symptoms: excessive straining, a sense of incomplete evacuation, failed or lengthy attempts to defecate, hard stools, and decreased stool frequency. A detailed (...) history and physical examination, including a digital rectal examination, is the first step in the evaluation of constipation. Diagnostic evaluation may include a colonoscopy if indicated, colonic transit study, anorectal manometry, and a balloon expulsion study. Initial treatment consists of lifestyle modification and laxatives. Medical treatment should be tailored to the underlying aetiology. Patients who do not respond to medical treatment may need specialised evaluation for pelvic floor

BMJ Best Practice2018

12. Constipation in children

Constipation in children Constipation in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Constipation in children Last reviewed: August 2018 Last updated: March 2018 Summary Childhood constipation is typically characterised by infrequent bowel evacuations, large stools, and difficult or painful defecation. Symptoms may result from low fibre, poor nutrient, and/or insufficient water intake, which leads (...) to excessive hardening of the stool. This often starts as an acute problem but can progress to faecal impaction and chronic constipation. Particularly in young children, any cause of painful defecation may provoke active withholding. Withholding may worsen the constipation and lead to a vicious cycle. Duration of constipation and amount of stool burden may depend on capacity of the child's rectum, the degree of megarectum, and other factors including rectal sensory function. After faecal disimpaction

BMJ Best Practice2018

13. Effects of Interferential Electrical Stimulation Plus Pelvic Floor Muscles Exercises on Functional Constipation in Children: A Randomized Clinical Trial

Effects of Interferential Electrical Stimulation Plus Pelvic Floor Muscles Exercises on Functional Constipation in Children: A Randomized Clinical Trial 29257143 2017 12 19 1572-0241 2017 Dec 19 The American journal of gastroenterology Am. J. Gastroenterol. Effects of Interferential Electrical Stimulation Plus Pelvic Floor Muscles Exercises on Functional Constipation in Children: A Randomized Clinical Trial. 10.1038/ajg.2017.459 Functional constipation is a common condition in children. We (...) assessed the effectiveness of combined interferential (IF) electrical stimulation and pelvic floor muscle (PFM) exercises on functional constipation in children. We conducted a single-center, double-blind randomized clinical trial study during 2014-2017 in Tehran, Iran. Ninety children, aged 5-13 years, who fulfilled Rome III criteria were enrolled and randomly assigned into two treatment groups. Case group (n=45) underwent IF electrical stimulation and PFM exercises, whereas the control group (n=45

EvidenceUpdates2018

14. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer

Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer 28968171 2017 12 11 2017 12 11 1527-7755 35 34 2017 Dec 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. 3859-3866 10.1200/JCO.2017.73.0853 Purpose Opioid-induced constipation (OIC) is a frequent (...) of Japanese Foundation for Cancer Research; and Narikazu Boku, National Cancer Center Hospital, Tokyo, Japan. eng Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial 2017 10 02 United States J Clin Oncol 8309333 0732-183X 0 Analgesics, Opioid 0 naldemedine 5S6W795CQM Naltrexone IM Adult Aged Analgesics, Opioid adverse effects therapeutic use Constipation chemically induced drug therapy Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule

EvidenceUpdates2017

15. Low-Dose Linaclotide (72 mug) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Low-Dose Linaclotide (72 mug) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial 29091082 2017 11 01 2017 11 01 1572-0241 2017 Aug 22 The American journal of gastroenterology Am. J. Gastroenterol. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. 10.1038/ajg.2017.230 Linaclotide is a guanylate cyclase-C agonist approved in the United States, Canada, and Mexico at a once (...) -daily 145-μg dose for the treatment of chronic idiopathic constipation (CIC); a once-daily 72-μg dose for CIC recently received FDA approval. The trial objective was to evaluate the efficacy and safety of a 72-μg linaclotide dose in CIC patients. This double-blind, placebo-controlled trial randomized patients with CIC (Rome III criteria) to once-daily linaclotide 72 μg or 145 μg, or placebo for 12 weeks. The primary endpoint, 12-week complete spontaneous bowel movement (CSBM) overall responder

EvidenceUpdates2017

16. Constipation

Constipation Constipation | ONS Search the ONS website Constipation Constipation PEP Topics Constipation is defined as the decreased passage of stool characterized by infrequent bowel movements, hard stool, sensation of abdominal bloating or cramping, straining with bowel movements, and feeling of incomplete evacuation. Constipation can be a symptom of the cancer itself because of pressure that can partially or totally occlude the bowel. Constipation also can occur because of problems (...) of immobility or dehydration as a result of cancer treatment that directly affects the bowel or innervation of the gastrointestinal tract and as a result of medication. Opioid-induced constipation is a problem in patients who require opioids for pain management. The incidence of constipation among patients with cancer has not been well defined. In the palliative care population, prevalence of 40%–64% has been reported, and the symptom can be as high as 70%–100% among hospitalized patients with cancer. Click

Oncology Nursing Society Putting Evidence into Practice (PEP)2017

17. Naloxegol (Moventig) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation

Naloxegol (Moventig) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation Prescrire IN ENGLISH - Spotlight ''Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation'', 1 October 2017 {1} {1} {1} | | > > > Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation FEATURED REVIEW Naloxegol tablets have been authorised in the European Union for adults with troublesome opioid-induced constipation despite laxative therapy. Does naloxegol relieve discomfort in these patients? What

Prescrire2017

19. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer 28445097 2017 04 26 2017 06 07 1527-7755 35 17 2017 Jun 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer. 1921-1928 10.1200/JCO (...) .2016.70.8453 Purpose This randomized, double-blind, multicenter study aimed to determine the dose of naldemedine, a peripherally-acting μ-opioid receptor antagonist, for future trials by comparing the efficacy and safety of three doses of naldemedine versus placebo in patients with cancer and opioid-induced constipation. Methods Patients ≥ 18 years old with cancer, an Eastern Cooperative Oncology Group performance status ≤ 2, who had been receiving a stable regimen of opioid analgesics for ≥ 2 weeks, had

EvidenceUpdates2017

20. Symproic (naldemedine) Tablets - For the treatment of opioid-induced constipation

Symproic (naldemedine) Tablets - For the treatment of opioid-induced constipation Symproic (naldemedine) Tablets U.S. Department of Health and Human Services Search FDA Submit search Symproic (naldemedine) Tablets Symproic Company: Shionogi Inc. Application No.: 208854 Approval Date: 03/23/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

FDA - Drug Approval Package2017